TP53 is mutated in more than 90% of ovarian cancers whereas less than 15% of acute myeloid leukemias (AML) have TP53 mutations, suggesting that there may be some tissue-specific requirements for loss of wild type or gain of mutant p53 functions [25]. This evidence concerns the gene TP53 and ovarian carcinoma.